2ⁿᵈ Edition of the Cancer R&D World Conference 2026

Scientific Sessions

Cancer Vaccines

Cancer vaccines represent a rapidly evolving frontier in immuno-oncology, designed to train the immune system to recognize and eliminate tumor-specific antigens. Cancer vaccines differ from traditional vaccines in that they treat or prevent recurrence of malignancies rather than preventing infectious diseases. The accelerated discovery of neoantigens and the exciting developments with mRNA technology have now opened new avenues for truly personalized vaccines matched to everyone’s tumor. Therapeutic and preventive cancer vaccines have shown impressive promise in various tumor types, offering a chance for durable remission and long-term protection.

At the Cancer Research and Development Conference 2026, this session will highlight recent breakthroughs in vaccine design, delivery systems, and combination strategies with checkpoint inhibitors and adjuvants. Experts will discuss challenges in clinical translation, immune tolerance, and patient selection. Join us as we explore how innovative cancer vaccines are reshaping the landscape of cancer treatment, bringing us closer to a future where immunity and precision converge to defeat cancer.

Related Sessions

Current Landscape and Future Directions of Oncology Research
Oncogenic Signaling Pathways and Therapeutic Targets
Emerging Biomarkers for Cancer Detection and Prognosis
Cancer Prevention and Early Detection Strategies
Immuno-Oncology and Cell-Based Therapies
Innovations in Immuno-Oncology
Cytokine Modulation and Immune Adjuvants in Cancer Immunotherapy
Cancer Vaccines
CAR-T Cell Therapy: Clinical Progress and Challenges
Next-Generation Cell and Gene Therapies in Oncology
Liquid Biopsy and Circulating Tumor DNA (ctDNA) Diagnostics
Companion Diagnostics
Artificial Intelligence and Machine Learning in Precision Oncology
Next-Generation Targeted Therapies: KRAS, HER2, BRAF, and NRAS
Overcoming Drug Resistance: Mechanisms and Solutions
Oncology Pipeline
Trends in Antibody–Drug Conjugates (ADCs)
Launch of Novel mAb Products for Cancer Therapy